The delay exposes a capital-allocation vulnerability in the CCA program's first increment. Anduril absorbed pre-production costs (facility, long-lead buys) expecting FY27 to flow by late calendar 2026; if Congress extends the CR past December, the company's carry-forward liability grows while the Air Force's 500-drone target slips further.
General Atomics faces the same math on its facility. The real risk is not whether production eventually starts, but whether a protracted CR forces both primes to absorb carrying costs that compress margins on Increment 2 negotiations — and whether the Air Force's 2032 target becomes unaffordable once the first lot's unit cost reflects that overhead.
Anduril's Arsenal-1 facility can produce 150 Fury drones annually, but the current continuing resolution (through December 11) blocks new program starts — forcing a choice between a four-month production delay or a CR anomaly that would require explicit Air Force advocacy to Congress.
If the Air Force fails to secure an exemption and negotiations slip past December, the CCA program's first production lot misses its 2027 ramp, pushing the 500-drone service goal beyond 2032. The constraint is not engineering or manufacturing capacity — it's the appropriations calendar, and Anduril has already burned private capital betting on December passage.
Has the Air Force formally requested a CR anomaly to allow CCA production to commence before FY27 passage, or is it waiting for December appropriations?
Strategic intelligence, synthesized daily — with a public track record. Every call graded against what actually happened.